CymaBay Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de CymaBay Therapeutics han disminuido a una tasa media anual de -5.3%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.2% anualmente. Los ingresos han ido creciendo a una tasa media de 98.2% al año.

Información clave

-5.3%

Tasa de crecimiento de los beneficios

4.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	98.2%
Rentabilidad financiera	-36.1%
Margen neto	-339.1%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

Desglose de ingresos y gastos

Cómo gana y gasta dinero CymaBay Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:CBAY Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	31	-105	52	0
30 Sep 23	31	-90	39	26
30 Jun 23	31	-81	33	26
31 Mar 23	0	-107	27	26
31 Dec 22	0	-106	25	0
30 Sep 22	0	-106	24	21
30 Jun 22	0	-104	23	21
31 Mar 22	0	-100	24	21
31 Dec 21	0	-90	23	0
30 Sep 21	0	-79	22	4
30 Jun 21	0	-68	21	8
31 Mar 21	0	-55	18	11
31 Dec 20	0	-51	17	13
30 Sep 20	0	-65	16	13
30 Jun 20	0	-80	17	15
31 Mar 20	0	-93	18	17
31 Dec 19	0	-103	19	19
30 Sep 19	0	-93	19	20
30 Jun 19	0	-85	18	17
31 Mar 19	0	-79	17	16
31 Dec 18	0	-73	14	14
30 Sep 18	5	-58	13	12
30 Jun 18	5	-48	12	10
31 Mar 18	5	-39	12	8
31 Dec 17	10	-28	12	7
30 Sep 17	5	-29	12	6
30 Jun 17	5	-27	12	6
31 Mar 17	5	-25	11	6
31 Dec 16	0	-27	10	6
30 Sep 16	0	-26	9	6
30 Jun 16	0	-26	9	6
31 Mar 16	0	-20	9	6
31 Dec 15	0	-16	9	5
30 Sep 15	0	-22	9	6
30 Jun 15	0	-22	9	7
31 Mar 15	0	-24	8	4
31 Dec 14	0	-32	8	4
30 Sep 14	0	208	8	4
30 Jun 14	0	257	7	2
31 Mar 14	0	240	6	3
31 Dec 13	0	244	5	3
30 Sep 13	0	11	4	4
30 Jun 13	3	-36	4	4
31 Mar 13	3	-23	4	5

Ingresos de calidad: CBAY actualmente no es rentable.

Margen de beneficios creciente: CBAY actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CBAY no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 5.3% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CBAY en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CBAY no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (54.6%).

Rentabilidad financiera

Alta ROE: CBAY tiene una rentabilidad financiera negativa (-36.05%), ya que actualmente no es rentable.

CymaBay Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

CymaBay Therapeutics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

CymaBay Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Chief Medical Officer recently bought US$61k worth of stock

Why I've Taken A 'Starter' Position In CymaBay Therapeutics

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Cymabay Therapeutics, Inc. Announces Positive Data from Its Previously Completed Phase 2 Study and the Enhance Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

Independent Director has left the company

Price target decreased to US$12.00

CymaBay Therapeutics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

New 90-day low: US$5.32

We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely